Profiel
Blake Mandell is the founder of Transcend Therapeutics, Inc. (New York).
He held the title of Chief Executive Officer at the company, although he is no longer active in that role.
Actieve functies van Blake Mandell
Bedrijven | Functie | Begin |
---|---|---|
Transcend Therapeutics
Transcend Therapeutics BiotechnologyHealth Technology Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Transcend Therapeutics
Transcend Therapeutics BiotechnologyHealth Technology Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access. | Health Technology |